Somatic Advantage 500 Advanced (DNA+RNA)

The Comprehensive Panel for Solid Cancers
Test Code
SLS162003
Book Now

What is Somatic Advantage 500 Advanced?

This is an ultra-comprehensive next-generation sequencing (NGS) test that analyzes mutations in 523 genes using DNA sequencing and fusions in 55 genes using RNA sequencing, along with key immunotherapy biomarkers—Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI). It is designed for deep tumor profiling across all solid cancers.

Genes Covered/ No. of Genes/ Biomarkers Covered: 523 Genes, 55 Fusions, Tumor Mutation Burden (TMB), Microsatellite Instability (MSI)

Illumina TSO 500: Comprehensive genomic profiling with FDA approval

SA500 Advanced uses the TSO 500 test to detect key genetic changes, identifies NTRK and RET fusions, offers pan-cancer companion diagnostic capabilities in a single FDA-approved IVD kit

Who Is This Test For?

Patients with advanced, rare, or treatment-refractory cancers who are being considered for targeted therapies, immunotherapy, or clinical trials

Key Features

  • Comprehensive Coverage: Covers AMP Tier I/II/III variants in 523 genes
  • Broad Genetic Spectrum: Covers SNVs/InDels (523 genes), CNVs (59 genes), and gene fusions (55 genes)
  • Empowers Immuno-Oncology: Advanced algorithms enable precise analysis of TMB and MSI
  • Unparalleled Reliability: Utilizes UMI-based library preparation for high sensitivity and accuracy
  • Clear Insights: Simple, easy-to-read reports covering diagnostic, prognostic, and therapeutic biomarkers, along with relevant therapy recommendations and clinical trials
  • Strong Somatic Knowledge Base: 523 genes, 20,000 variants, 100+ FDA-approved drugs, and 4,844 pathway interactions with manually curated molecular variant summaries and clinical therapy recommendations
  • Analytical Sensitivity: Analytical sensitivity >96% at 5% LOD, Analytical Specificity >99%
  • Coverage: Pre-UMI coverage >2000x, Post-UMI coverage >500x
  • Advanced Technology: State-of-the-art sequencing with Illumina NovaSeq™ X Plus
  • Assured Quality: Backed by robust validation and CAP/NABL accreditations

Clinical Applications

  • Identifies actionable mutations for targeted treatment selection
  • Assesses TMB and MSI to support immunotherapy decisions
  • Supports enrollment in clinical trials requiring extensive molecular profiling

All Solid Tumors, Comprehensive Profiling

Contact Us